Recent News

• 02.04.2026 - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
• 01.30.2026 - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
• 12.18.2025 - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
• 12.10.2025 - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
• 12.01.2025 - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
• 12.01.2025 - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
• 11.24.2025 - ProMIS Neurosciences Announces Reverse Stock Split
• 11.12.2025 - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Recent Filings

• 02.02.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.30.2026 - 8-K Current report
• 01.30.2026 - EX-99.1 EX-99.1
• 12.16.2025 - 8-K Current report
• 11.24.2025 - 8-K Current report
• 11.24.2025 - EX-99.1 EX-99.1
• 11.19.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 8-K Current report